Asset Details
Do you wish to reserve the book?
Eligibility of Sacubitril–Valsartan in a Real-World Heart Failure Population: A Community-Based Single-Centre Study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Eligibility of Sacubitril–Valsartan in a Real-World Heart Failure Population: A Community-Based Single-Centre Study
Do you wish to request the book?
Eligibility of Sacubitril–Valsartan in a Real-World Heart Failure Population: A Community-Based Single-Centre Study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Eligibility of Sacubitril–Valsartan in a Real-World Heart Failure Population: A Community-Based Single-Centre Study
2018
Overview
Abstract
Aims
This study aims to investigate the eligibility of the Prospective Comparison of Angiotensin Receptor–Neprilysin Inhibitor (ARNI) with ACE inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) study to a real-world heart failure population.
Methods and results
Medical records of all heart failure patients living within the catchment area of Umeå University Hospital were reviewed. This district consists of around 150 000 people. Out of 2029 patients with a diagnosis of heart failure, 1924 (95%) had at least one echocardiography performed, and 401 patients had an ejection fraction of ≤35% at their latest examination. The major PARADIGM-HF criteria were applied, and 95 patients fulfilled all enrolment criteria and thus were eligible for sacubitril–valsartan. This corresponds to 5% of the overall heart failure population and 24% of the population with ejection fraction ≤ 35%. The eligible patients were significantly older (73.2 ± 10.3 vs. 63.8 ± 11.5 years), had higher blood pressure (128 ± 17 vs. 122 ± 15 mmHg), had higher heart rate (77 ± 17 vs. 72 ± 12 b.p.m.), and had more atrial fibrillation (51.6% vs. 36.2%) than did the PARADIGM-HF population.
Conclusions
Only 24% of our real-world heart failure and reduced ejection fraction population was eligible for sacubitril–valsartan, and the real-world heart failure and reduced ejection fraction patients were significantly older than the PARADIGM-HF population. The lack of data on a majority of the patients that we see in clinical practice is a real problem, and we are limited to extrapolation of results on a slightly different population. This is difficult to address, but perhaps registry-based randomized clinical trials will help to solve this issue.
Publisher
Oxford University Press,John Wiley and Sons Inc
Subject
/ Aged
/ Aminobutyrates - administration & dosage
/ Angiotensin Receptor Antagonists - administration & dosage
/ Dose-Response Relationship, Drug
/ Eligibility Determination - methods
/ Enzymes
/ Female
/ Heart Failure - drug therapy
/ Heart Failure - epidemiology
/ Heart Failure - physiopathology
/ HFrEF
/ Humans
/ Male
/ Original
/ Peptides
/ Population Surveillance - methods
/ Stroke Volume - drug effects
